TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01905423

Intervention type: DRUG
Intervention: Albendazole (annual)
Description: Albendazole 400 mg pnce annually

Intervention type: DRUG
Intervention: Albendazole (annual)
Description: Albendazole 400 mg pnce annually

Intervention type: DRUG
Intervention: Albendazole (annual)
Description: Albendazole 400 mg pnce annually

Intervention type: DRUG
Intervention: Diethylcarbamazine (annual)
Description: Diethylcarbamazine 6 mg/kg once annually

Intervention type: DRUG
Intervention: Diethylcarbamazine (annual)
Description: Diethylcarbamazine 6 mg/kg once annually

Intervention type: DRUG
Intervention: Diethylcarbamazine (annual)
Description: Diethylcarbamazine 6 mg/kg once annually
Study: NCT02982720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sylatron
Description: Sylatron will be administered subcutaneously.
Study: NCT02085837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Additional education will be provided by nurses to improve communication and reduce fragmentation of care.
Study: NCT03483532

Intervention type: DIETARY_SUPPLEMENT
Intervention: dry cocoa extract
Description: (Theobroma cacao, fruit), 2 capsules of 750 mg per individual, dosed at a rate of one during the breakfast and another during dinner.
Study: NCT01905423

Intervention type: DRUG
Intervention: Albendazole (semiannual)
Description: Albendazole 400 mg twice annually

Intervention type: DRUG
Intervention: Albendazole (semiannual)
Description: Albendazole 400 mg twice annually
Study: NCT03071666

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A tablet identical to the vitamin supplement but containing no vitamin B12
Study: NCT01905423

Intervention type: DRUG
Intervention: Diethylcarbamazine (semiannual)
Description: Diethylcarbamazine 6 mg/kg twice annually

Intervention type: DRUG
Intervention: Diethylcarbamazine (semiannual)
Description: Diethylcarbamazine 6 mg/kg twice annually
Study: NCT01146860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNO 1016
Description: sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
Study: NCT04425928

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: occupational therapy based activity training programs
Description: Occupational therapy based activity training programs in which exercises based on physiotherapy are put into the purposeful activities at vestibular rehabilitation.
Study: NCT01146860

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
Study: NCT02085837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily weight measurement and monitoring
Description: Monitor weight to avoid problems related to hypervolemia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Universal Dietary education
Description: To improve diet and health
Study: NCT03534648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 administered Day 7-14
Description: PF-06865571 administered Q12hr on Days 7-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 administered Day 1-14
Description: PF-06865571 administered Q12hr on Day 7-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 administered Day 1-14
Description: PF-05221304 administered Q12hr on Days 1-14
Study: NCT02085837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Medication will be reviewed by nurses to detect any discrepancies to reduce medication error.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused advanced directive program
Description: Education will be provided to increase awareness and encourage patients to have advanced directive.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Countdown to fistula program
Description: To reduce the number of patients starting dialysis with catheter in place, comprehensive stepwise intervention will be provided by nurses to ensure arterio-venous (AV) fistula placement in all appropriate patients, with coordinated follow up and failure recovery processes.
Study: NCT01196130

Intervention type: BEHAVIORAL
Intervention: Cancer Symptom Questionnaire
Description: 5 minute questionnaire(s) completed at each study visit.

Intervention type: OTHER
Intervention: Biomarker Testing
Description: Blood draw at each study visit for biomarker and cytokine testing.
Study: NCT01990300

Intervention type: DRUG
Intervention: Alogliptin/Pioglitazone
Description: Alogliptin/Pioglitazone combination tablets
Study: NCT02552433

Intervention type: DIETARY_SUPPLEMENT
Intervention: protein intake assessment and optimisation
Study: NCT01215708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: tamsulosin 0,4mg every night for 30 consecutive days
Study: NCT04425928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy based exercise training programs
Description: Cawthorne-cooksey exercises were performed at vestibular rehabilitation
Study: NCT04877210

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Insulin
Description: Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Insulin
Description: Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Insulin
Description: Insulin (Actrapid) diluted in Normal Saline is given to participant 1 drop to both eyes 4 times per days for 4 weeks
Study: NCT00633256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: 50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
Study: NCT05710562

Intervention type: OTHER
Intervention: Name not applicable
Description: In this study, we do not provide any type of intervention but only require the fulfillment of self-report tools by patients during their routine outpatients visit.
Study: NCT03534648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 administered Day 7-14
Description: PF-05221304 administered Q12hr Days 7-14
Study: NCT01215708

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin
Description: tamsulosin 0,4mg every night for 30 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: tamsulosin 0,4mg every night for 30 consecutive days
Study: NCT02247414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
Study: NCT02173600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-level Intensive dietary Counselling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual-level Intensive Dietary Counselling
Study: NCT02095860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA FDC
Description: Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA FDC
Description: Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA FDC
Description: Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
Study: NCT02247414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
Study: NCT03464240

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: glucose drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: control
Study: NCT02987439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: The intervention is pulmonary rehabilitation
Study: NCT04280120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilisation
Description: Neural mobilization was applied by gently holding the lower part of the ear between the index finger and thumb. The thumb was placed at the opening of the external auditory meatus and the index finger placed behind the auricle of the ear (Figure 2). The intensity of auricular traction was determined by the patient reporting the level of discomfort. The patient tolerated 3-4 sets of gentle horizontal traction and circular movement 25 times each with 5 seconds rest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy
Description: Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Massage therapy consisting of tapping, effleurage and finger and thumb kneading for 15-16 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Faradic electrical stimulation
Description: Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Faradic electrical stimulation
Description: Faradic electrical stimulation with anode electrode at the back of the neck and cathode over the nerve trunk anterior to the earlobe. The cathodic pen electrode was used to locate the facial nerve trunk for stimulation manually. (Biphasic current, pulse time 300 microseconds, frequency 60 Hz, 20 contractions, Rest 10 seconds). The total treatment time was 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Exercises in front of the mirror like raising the eyebrow, clinching the teeth (patient trying to see his clenched teeth in the mirror), smiling and performing other facial expressions for 12-15 minutes.
Study: NCT02247414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Molecular Weight Heparin
Description: From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin
Description: From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Study: NCT01225835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menotrophin
Description: Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitrophin alpha
Description: Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
Study: NCT02003833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poly-L-lactic acid
Description: Sculptra injections

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: saline injections
Study: NCT01225835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
Study: NCT01627158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol Easyhaler
Description: Budesonide/formoterol Easyhaler
Study: NCT01225835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choriongonadotropin
Description: 10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles \>+17 mm diameter as shown by pelvic ultrasound examination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choriongonadotropin
Description: 10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles \>+17 mm diameter as shown by pelvic ultrasound examination.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
Study: NCT03085550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: Single treatment fat grafting infiltrated into diabetic ulcer wound
Study: NCT01877655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP0113
Description: Intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study: NCT01857895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
Study: NCT04358458

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN3009
Description: GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN3009
Description: GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered by subcutaneous (SC) injections in cycles of 28 days
Study: NCT01627158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler
Description: Symbicort Turbuhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Charcoal and Budesonide/formoterol Easyhaler
Description: Charcoal and Budesonide/formoterol Easyhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Charcoal and Symbicort Turbuhaler
Description: Charcoal and Symbicort Turbuhaler
Study: NCT04579770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: 75g ketone ester in the form of a drink \[96% (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, Oxfordshire, UK)\] will be provided.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: 75g ketone ester in the form of a drink \[96% (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, Oxfordshire, UK)\] will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate - widely accessible food ingredient will be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate - widely accessible food ingredient will be provided.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03522363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Streptococcus dentisani CECT7746
Description: Treatment will be applied topically as an adhesive gel with a dental splint
Study: NCT02517489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
Study: NCT04260932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD20 Dual-CAR-T cells
Description: CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.
Study: NCT02581423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m\^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
Study: NCT02399917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Given IV
Study: NCT03572777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant therapy
Description: Amoxicillin ('Amoksicilin') 1 g bid 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant therapy
Description: Clarithromycin ('Makcin') 500 mg bid for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant therapy
Description: Metronidazole ('Medazol') 500 mg bid for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant therapy
Description: Esomeprazole ('Emanera') 40 mg bid for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid therapy
Description: Amoxicillin ('Amoksicilin') 1 g bid 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid therapy
Description: Esomeprazole ('Emanera') 40 mg bid for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid therapy
Description: Clarithromycin ('Makcin') 500 mg bid for the last 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid therapy
Description: Metronidazole ('Medazol') 500 mg bid for the last 7 days
Study: NCT00113386

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim
Description: Consolidation chemotherapy

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim
Description: Consolidation chemotherapy

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: pegfilgrastim
Description: Consolidation chemotherapy

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: pegfilgrastim
Description: Consolidation chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel

Intervention type: PROCEDURE
Group type: OTHER
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: neoadjuvant therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study: NCT03341156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kcentra
Description: Kcentra will be administered in 2 divided doses; Pre-bypass (5-10 units/kg based on body weight and preoperative INR and post-protamine based of the pre-bypass dose and the preoperative INR; daily maximum dose not to exceed 5000 IU (50 IU/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frozen Plasma Product, Human
Description: If the patient is randomized to receive standard transfusion they will receive 2 U of fresh frozen plasma intravenously before cardiopulmonary bypass and then up to 4-8 U of plasma added to the cardiopulmonary bypass reservoir during rewarming.
Study: NCT02115347

Intervention type: DRUG
Group type: OTHER
Intervention: Ertugliflozin 15 mg
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Description: Tablet